Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 5.51 USD 12.68% Market Closed
Market Cap: 307.1m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+96%
Revenue
Forecast
+24%
Operating Income
Forecast
+2%
Net Income
Forecast
+5%

Wall Street
Price Targets

FHTX Price Targets Summary
Foghorn Therapeutics Inc.

Wall Street analysts forecast FHTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FHTX is 10.78 USD with a low forecast of 4.04 USD and a high forecast of 14.7 USD.

FHTX Lowest Forecast
Wall Street Target
4.04 USD
27% Downside
FHTX Average Forecast
Wall Street Target
10.78 USD
96% Upside
FHTX Highest Forecast
Wall Street Target
14.7 USD
167% Upside
Lowest
Price Target
4.04 USD
27% Downside
Average
Price Target
10.78 USD
96% Upside
Highest
Price Target
14.7 USD
167% Upside
Foghorn Therapeutics Inc. Competitors:
Price Targets
BEAM
Beam Therapeutics Inc
107% Upside
688520
Sinocelltech Group Ltd
25% Downside
TRDA
Entrada Therapeutics Inc
176% Upside
ELUT
Elutia Inc
211% Upside
BEAM
Beam Therapeutics Inc
107% Upside
688520
Sinocelltech Group Ltd
25% Downside
TRDA
Entrada Therapeutics Inc
176% Upside
ELUT
Elutia Inc
211% Upside
688235
Beigene Ltd
28% Upside
ALT
Altimmune Inc
370% Upside
302440
SK Bioscience Co Ltd
18% Downside
TWST
Twist Bioscience Corp
35% Upside

Revenue
Forecast

Revenue Estimate
Foghorn Therapeutics Inc.

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 3 years is 24%.

N/A
Past Growth
24%
Estimated Growth
Estimates Accuracy
-28%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Foghorn Therapeutics Inc.

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Foghorn Therapeutics Inc.

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss
What are analyst estimates?

See Also

Summary
FHTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
FHTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FHTX stock valuation using valuation multiples.
Wall Street Estimates
FHTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FHTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FHTX's stock price target?
Price Target
10.78 USD

According to Wall Street analysts, the average 1-year price target for FHTX is 10.78 USD with a low forecast of 4.04 USD and a high forecast of 14.7 USD.

What is Foghorn Therapeutics Inc.'s Revenue forecast?
Projected CAGR
24%

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 3 years is 24%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 266,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.